Semaglutide is a medication used to treat type 2 diabetes. It belongs to the class of glucagon-like peptide-1 (GLP-1) receptor agonists, which work by increasing insulin secretion and reducing appetite. Recently, a higher dose of semaglutide has been approved by the FDA as a treatment for obesity, with the brand name Wegovy. It has been shown to be effective in aiding weight loss in overweight and obese individuals when combined with diet and exercise. Semaglutide works by suppressing appetite and reducing caloric intake, leading to sustained weight loss.

The most common side effects of Ozempic® may include nausea, vomiting, diarrhea, stomach (abdominal) pain, and constipation. This is why it’s good to start at a low dosage and titrate slowly. Ozempic® may cause serious side effects. You should notify your healthcare practitioner if you get changes in vision, low blood sugar (hypoglycemia), kidney problems, pancreatitis, or any serious allergic reactions. Symptoms of low blood sugar include sudden sweating, shaking, fast heartbeat, hunger, blurred vision, dizziness, or tingling hands/feet.

You should not take Semaglutide (Ozempic) if you are allergic to it or any of its ingredients. You should not take Ozempic if you or any of your family has ever had MTC or MEN 2. Medullary thyroid cancer (MTC) is an aggressive form of thyroid cancer. Multiple endocrine neoplasia type 2 (MEN2) is a rare genetic polyglandular cancer syndrome, characterized by the 100% prevalence of medullary thyroid carcinoma (MTC)..

You should stop using Ozempic 2 months before you plan to become pregnant or if you are breastfeeding. It is not known if Ozempic will harm an unborn baby or if it passes into breast milk. It is also not known if Ozempic can be used in people who have had pancreatitis. Ozempic is not a substitute for insulin and is not for use in people with type 1 diabetes or people with diabetic ketoacidosis. It has not been studied in children under 18 years of age. Let me know if you have ever had pancreas or kidney trouble. Limit alcohol while taking this medication because it can increase your risk of developing low blood sugar.

Semaglutide is a prescription medication used for weight loss in adults who have obesity or are overweight and have at least one weight-related health problem. The medication is taken once a week via injection. When starting semaglutide, it may take a few weeks to notice weight loss, and it is recommended to continue treatment for at least 16 weeks to evaluate its effectiveness. The exact duration of semaglutide’s effects may vary from person to person and may depend on factors such as individual metabolism, diet, and exercise habits.

Semaglutide is a medication commonly prescribed for weight loss. It is a glucagon-like peptide-1 (GLP-1) receptor agonist that helps control blood sugar levels in people with type 2 diabetes. While semaglutide can cause a decrease in blood sugar levels, it is not typically associated with hypoglycemia (low blood sugar) in people without diabetes. However, for individuals with diabetes, hypoglycemia may be a side effect of semaglutide use, especially when combined with other blood sugar-lowering medications. It is important for individuals with diabetes who are taking semaglutide to monitor their blood sugar levels regularly

Tirzepatide is a prescription injection that aids in the weight loss process. Tirzepatidemimicks the effects of a naturally occurring gut hormones called GLP-1 and GIP, which helps to regulate blood sugar levels in the body.

Tirzepatide is a dual agonist, meaning it works on two receptors in the body, GLP-1 and GIP. This medication slows down the rate at which your stomach sends food to your large intestine. This results in slower digestion (which improves blood sugar) and a longer feeling of fullness. It also stimulates the pancreas to produce more insulin, removing sugar from the bloodstream..

Tirzepatide may cause side effects such as nausea, diarrhea, and vomiting. However, the risk of these side effects is generally considered to be low, and most people are able to tolerate the medication well. Typically, side effects of Tirzepatide improve after the first four weeks of therapy.

Tirzepatide is not recommended for anyone who has a history of medullary thyroid carcinoma (a rare form of thyroid cancer), or a condition called Multiple Endocrine Neoplasia syndrome type 2. Additionally, Tirzepatide is not recommended for those with Type 1 Diabetes.

It produces an amazing 20% weight loss on average and is the first drug that targets both GLP-1 and GIP, resulting in more effective glycemic control and appetite suppression. Reductions in body weight have also been shown to be greater with tirzepatide versus semaglutide and increased with the dose: 1.9 kg for 5 mg, 3.6 kg for 10 mg, and 5.5 kg for 15mg.